Evaxion A (EVAX) Retained Earnings (2019 - 2026)
Evaxion A's (EVAX) quarterly Retained Earnings came in at -$133.7 million in Q1 2026, down 11.33% YoY from -$150.8 million in Q1 2025, and down 204.89% on a QoQ basis from $127.5 million in Q4 2025.
Evaxion A (EVAX) Retained Earnings (2019 - 2026) Analysis & Trends
Evaxion A (EVAX) has 8 years of Retained Earnings data on file, last reported at -$133.7 million in Q1 2026.
- Quarterly Retained Earnings fell 11.33% year-over-year to -$133.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.7 million (down 11.33% YoY) and the FY2025 annual result came in at $127.5 million, up 207.55% from the prior year.
- Retained Earnings declined to -$133.7 million in Q1 2026, from $127.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $130.1 million in Q3 2025 to a low of -$112.0 billion in Q1 2024.
- A 5-year average of -$7.0 billion and a median of -$87.0 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings plunged 138275.88% — and 2025, when it jumped 207.55%.
- Tracing EVAX's Retained Earnings over 5 years: stood at $90.3 million in 2022, then slumped by 219.62% to -$108.0 million in 2023, then dropped by 9.79% to -$118.5 million in 2024, then jumped by 207.55% to $127.5 million in 2025, then tumbled by 204.89% to -$133.7 million in 2026.
- The last three Retained Earnings figures came in at -$133.7 million (Q1 2026), $127.5 million (Q4 2025), and $130.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 4.38 Bn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | -133.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -133.72 Mn |
| Dec 31, 2025 | 127.49 Mn |
| Sep 30, 2025 | 130.11 Mn |
| Jun 30, 2025 | -124.95 Mn |
| Mar 31, 2025 | -120.11 Mn |
| Dec 31, 2024 | -118.54 Mn |
| Jun 30, 2024 | -112.97 Mn |
| Mar 31, 2024 | -112.03 Bn |
| Dec 31, 2023 | -107.97 Mn |
| Sep 30, 2023 | -89.76 Mn |
| Jun 30, 2023 | -84.26 Mn |
| Mar 31, 2023 | 81.08 Mn |
| Dec 31, 2022 | 90.26 Mn |
| Sep 30, 2022 | 75.44 Mn |
| Jun 30, 2022 | 76.63 Mn |
| Mar 31, 2022 | 78.51 Mn |
| Dec 31, 2021 | 79.11 Mn |
| Sep 30, 2021 | 55.66 Mn |
| Jun 30, 2021 | 56.17 Mn |
| Mar 31, 2021 | 55.75 Mn |